You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR MEROPENEM; VABORBACTAM

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for meropenem; vaborbactam

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Department of Health and Human Services	Phase 3	2014-11-20	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Melinta Therapeutics, Inc.	Phase 3	2014-11-20	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	Phase 3	2014-11-20	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Department of Health and Human Services	Phase 3	2014-07-01	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Phase 3	2014-07-01	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	Phase 3	2014-07-01	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for meropenem; vaborbactam

Condition Name

Chart
Table

Condition Name for meropenem; vaborbactam
Intervention	Trials
Urinary Tract Infection Complicated	2
Ventilator-associated Bacterial Pneumonia	2
Acute Pyelonephritis	2
Healthy	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for meropenem; vaborbactam
Intervention	Trials
Infections	3
Infection	3
Communicable Diseases	2
Urinary Tract Infections	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for meropenem; vaborbactam

Trials by Country

Map
Table

Trials by Country for meropenem; vaborbactam
Location	Trials
United States	28
Brazil	4
Greece	2
Spain	2
Italy	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for meropenem; vaborbactam
Location	Trials
New Jersey	3
Illinois	3
Ohio	2
New York	2
Georgia	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for meropenem; vaborbactam

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for meropenem; vaborbactam
Clinical Trial Phase	Trials
Phase 3	3
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for meropenem; vaborbactam
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for meropenem; vaborbactam

Sponsor Name

Chart
Table

Sponsor Name for meropenem; vaborbactam
Sponsor	Trials
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	3
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	3
Department of Health and Human Services	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for meropenem; vaborbactam
Sponsor	Trials
Industry	8
U.S. Fed	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.